RNA therapies hold tremendous promise for treating genetic eye diseases. However, their development is limited by the lack of ...
CRISPR-Cas13d is increasingly used for RNA knockdowns, but off-target cleavage of near-cognate RNAs hinders its broader ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results